Evidence map›Paper›PMID 35035873›Full record

ArticleTherapeutic advances in endocrinology and metabolism2022

Qualitative evaluation of the symptoms and quality of life impacts of long-chain fatty acid oxidation disorders.

Rebecca Williams-Hall, Katie Tinsley, Eliza Kruger, Chloe Johnson, Alexandra Bowden, Tricia Cimms, Adam Gater

Open access · goldAbstract read
In one paragraph

Article in Therapeutic advances in endocrinology and metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Assessing Quality of Life in Genetic Cardiomyopathies: A Scoping Review.International journal of environmental research and public health · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Rebecca Williams-HallAdelphi Values Ltd., Adelphi Mill, Grimshaw Lane, Bollington SK10 5JB, Cheshire, UK.
Katie TinsleyAdelphi Values Ltd, Bollington, UK.
Eliza KrugerUltragenyx Pharmaceutical Inc., Novato, CA, USA.
Chloe JohnsonAdelphi Values Ltd, Bollington, UK.
Alexandra BowdenUltragenyx Pharmaceutical Inc., Novato, CA, USA.
Tricia CimmsUltragenyx Pharmaceutical Inc., Novato, CA, USA.
Adam GaterAdelphi Values Ltd, Bollington, UK.
Adelphi Group (United Kingdom) · GBUltragenyx Pharmaceutical (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLong-chain fatty acid oxidation disorders (LC-FAOD) are a group of rare autosomal-recessive genetic disorders characterized by metabolic deficiencies in which the body is unable to convert long-chain fatty acids into energy. To date, however, there is limited understanding of the patient experience of LC-FAOD.

methodsThe symptoms, observable signs, and quality of life (QoL) impacts associated with LC-FAOD were explored via a focus group (

resultsParticipants reported a wide range of signs and symptoms associated with LC-FAOD, broadly categorized as musculoskeletal, endocrine/nutritional/metabolic, neurological, gastrointestinal/digestive, sensory, cardiovascular, respiratory, urological, and constitutional. LC-FAOD were reported to have a significant impact on various aspects of patients' lives including physical functioning, participation in daily activities, emotional/psychological wellbeing, and social functioning. Lifestyle modifications (such as diet and exercise restrictions) were necessary because of the condition. Symptoms were typically episodic in presentation often arising or exacerbated during catabolic conditions such as prolonged exercise, fasting, physiological stress, and illness/infection. Symptoms were also commonly reported to lead to emergency room visits, hospitalization, and clinical complications.

conclusionLC-FAOD have a considerable impact on patients' lives. There is a high degree of concordance in the signs, symptoms, and impacts of LC-FAOD reported by patients, caregivers, and clinicians; however, there were many symptoms and impacts that were only reported by patients and caregivers, thus demonstrating that insights from patient/caregiver experience data are integral for informing medical product development and facilitating patient-centered care.

Indexed as

long-chain-fatty acid oxidation disordersmulti-methodmulti-perspectivepatient experiencequalitativequality of lifesymptoms

Identifiers

PMID35035873
PMCPMC8755934
OpenAlexW4205555896

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.